A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL)

Update Il y a 4 ans
Reference: EUCTR2004-005071-42

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to assess whether treatment with an enteric coated formulation of mycophenolic acid (MPA) permits higher MPA doses to be maintained, than treatment with standard MMF therapy, in patients with demonstrated susceptibility to gastro intestinal side effects


Inclusion criteria

  • renal transplantation